Eloralintide
vs Cagrilintide.
Compare eloralintide and cagrilintide by amylin receptor design, Phase 2 results, Phase 3 programs, tolerability evidence, and approval status.
What is the difference?
Eloralintide and cagrilintide are different investigational once-weekly amylin-pathway drugs, and no human head-to-head trial has compared them. Eloralintide is designed to preferentially activate the amylin 1 receptor, while cagrilintide is a long-acting amylin analogue with a broader receptor profile. Eloralintide has a completed 48-week Phase 2 trial and a recruiting ENLIGHTEN Phase 3 program. Cagrilintide has Phase 3 monotherapy evidence from REDEFINE 1 and an active standalone RENEW program. Their percentages came from different trials, durations, dose strategies, estimands, and placebo groups. Neither drug is FDA approved, and the evidence does not establish which is more effective, safer, or more tolerable for an individual.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Eloralintide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 19 matched NCT records
- Sponsor
- Eli Lilly and Company
Cagrilintide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 52 matched NCT records
- Sponsor
- Novo Nordisk
Eloralintide vs Cagrilintide: how direct is the evidence?
No participant in the cited sources was randomized between Eloralintide and Cagrilintide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Eloralintide
Selective amylin 1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 ENLIGHTEN program recruiting
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialCagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 11
- Results posted
- 1
- Recruiting site observations
- 613
matched NCT records
- Recruiting
- 10
- Results posted
- 2
- Recruiting site observations
- 170
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Eloralintide
Selective amylin 1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 ENLIGHTEN program recruiting
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT06230523 · NCT07321886 · NCT07282600 · NCT07369011 · NCT07353931 · NCT07392190 · NCT05295940
Cagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT03856047 · NCT05567796 · NCT07220642 · NCT07220759
Compare the field, then read the limit.
Both names are increasingly grouped as long-acting amylin alternatives, while online summaries frequently turn receptor selectivity or a larger trial percentage into a winner claim. Published discovery work did compare their pharmacology in animals, but those experiments cannot answer comparative human efficacy or safety. A useful comparison must separate receptor design, preclinical findings, randomized human trials, development stage, adverse-event reporting, and the distinct CagriSema combination.
| Field | Eloralintide | Cagrilintide | How to interpret it |
|---|---|---|---|
| Receptor design | Preferential amylin 1 receptor agonist | Long-acting amylin analogue with broader receptor activity | Selectivity is a pharmacology distinction, not proof of superior weight loss, tolerability, or clinical benefit. |
| Human evidence anchor | Up to a rounded 20% mean change at 48 weeks in Phase 2 | 11.8% at 68 weeks in the REDEFINE 1 monotherapy arm | Different trials, durations, estimands, escalation plans, and placebo responses prevent a direct percentage ranking. |
| Direct comparative evidence | Preclinical animal pharmacology compared with cagrilintide | No randomized human comparison with eloralintide | Animal comparisons can inform mechanism and cannot establish a human efficacy or safety winner. |
| Phase 3 path | Recruiting ENLIGHTEN program across several obesity-related populations | Standalone RENEW program plus the separate CagriSema program | Both programs are advanced, but different Phase 3 designs and combination contexts answer different questions. |
| Current status | Investigational and not FDA approved | Investigational and not FDA approved | Neither name identifies an approved retail product, prescribing instruction, pharmacy price, or verified online supply route. |
Why the headline numbers do not name a winner.
The eloralintide Phase 2 publication reported rounded 20% mean weight reduction at week 48 in the 9 mg and 6-to-9 mg groups under an efficacy estimand versus 0.4% with placebo. The cagrilintide monotherapy arm in REDEFINE 1 reported 11.8% at week 68 under a trial-product estimand versus 2.3% with placebo. Those figures were not randomized against each other and do not share a duration, estimand, dose plan, protocol, or placebo response. CagriSema results belong to cagrilintide plus semaglutide and cannot be credited to cagrilintide alone.
Keep the comparison honest.
- 01
Keep every percentage attached to its exact randomized trial, week, dose strategy, estimand, population, and placebo response.
- 02
Treat the published animal comparison as mechanistic evidence, not a substitute for a randomized human head-to-head trial.
- 03
Do not transfer CagriSema evidence to cagrilintide alone or treat an online vial as sponsor clinical material.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →